trial

CATIE-Alzheimer's Disease Trial

NCTId NCT00015548

as of 2026-07-01

Add to landscape Monitor this Ask about this

at a glance

— · Completed

Enrollment 450

Sponsored by National Institute of Mental Health (NIMH)

Synthesized from structured facts only — each point cited above.

Design & status

Phase

—

Status

Completed

Enrollment

450

Study type

Interventional

Allocation

Randomized

Model

Parallel

Masking

Double

Start

2001-03

Primary completion

—

Eligibility

ALL

Interventions & indications

Drugs

Olanzapine Quetiapine Risperidone Citalopram

Indications

Hallucinations Psychomotor Agitation Dementia Alzheimer's Disease Psychotic Disorders Delusions Behavioral Symptoms Alzheimer Disease

Investigators

Lon Schneider, MDPrincipal Investigator

Pierre Tariot, MDPrincipal Investigator

Sites

34 total

Tuscaloosa, United StatesIrvine, United StatesLos Angeles, United StatesLos Angeles, United StatesSan Diego, United StatesStanford, United StatesNew Haven, United StatesBoca Raton, United StatesHialeah, United StatesTampa, United StatesWest Palm Beach, United StatesAtlanta, United States